Meta Expands AI Training With Employee Activity Tracking Tools 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
NEW YORK, May 18, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) who purchased shares between August 12, 2014 and April 28, 2017. The action, which was filed in the USDC for the Eastern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
Shareholders have until July 11, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/intra-cellular-therapies-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
